Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s Halozyme Therapeutics has submitted a non-binding proposal to acquire Evotec for 11.00 euros per share in cash, implying a fully-diluted equity value of around 2.0 billion euros ($2.12 billion). 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Sitryx, a new, Oxford, UK-based biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces it has closed its Series A financing round. 8 October 2018
Pharmaceutical
A few of pharma's big companies, including Boehringer Ingelheim, Allergan and Roche were involved in acquisitions in September. 1 October 2018
Biotechnology
Swiss pharma giant Roche has made a third bolt-on acquisition this year, today taking control of Tusk Therapeutics. 28 September 2018
Biotechnology
It’s not often that the company announcing an acquisition sees a significant share price spurt, but this was certainly the case on Wednesday for Alexion Pharmaceuticals, which gained over 5.1% to $135.61. 27 September 2018
Pharmaceutical
Following a ‘letter of intent’ back in June, Florida, USA-based Nutriband (OTCQB: NTRB) has now announced the signing of the definitive acquisition agreement to acquire Carmel Biosciences. 27 September 2018
Biotechnology
In the context of a competitive, some say overheated, market for mergers and acquisitions, Johnson & Johnson’s $30 billion purchase of Swiss biotech Actelion could be seen as a value-destructive move for shareholders. 26 September 2018
Biotechnology
US biotech firm Cerecor has agreed to acquire Ichorion Therapeutics, a privately-held biopharmaceutical company focused on developing treatments and increasing awareness of inherited metabolic disorders known as Inborn Errors of Metabolism (IEMs). 26 September 2018
Pharmaceutical
Privately-held US firm Tris Pharma today announced the acquisition of NextWave Pharmaceuticals, a wholly-owned subsidiary of Pfizer, including two key attention deficit hyperactivity disorder (ADHD) treatments. 25 September 2018
Pharmaceutical
Among last week’s regulatory events, new of US Food and Drug Administration approval of Teva Pharmaceutical Industries’ migraine prophylaxis drug Ajovy (fremanezumab) is seen as a turning point for the Israeli company. There was also FDA approval for AstraZeneca’s leukemia drug Lumoxiti, and the agency lifted the partial clinical hold on Mersana’s XMT-1522 cancer drug, but the company’s shares fell. Allergan’s acquisition of medical aesthetics firm Bonti is seen as good news for the firm. On the research front, Viking Therapeutics soared on strong clinical data for its liver disease drug VK2809, but it may not be the first to come to the market. 23 September 2018
Pharmaceutical
New Jersey, USA-based rare diseases drugmaker Amicus Therapeutics has dived into the gene therapy sector. 21 September 2018
Pharmaceutical
Following a public comment period, the US Federal Trade Commission has approved a final order that settles charges that Catalan pharma-chemical company Grifols’ $286 million acquisition of USA-based Biotest Pharmaceuticals is anticompetitive and violates federal antitrust law. 19 September 2018
Pharmaceutical
Swiss drugmaker Vifor Pharma has upped its equity stake in ChemoCentryx, a company with a current focus on late-stage candidates for patients with rare kidney diseases. 18 September 2018
Pharmaceutical
The Antitrust Division of the US Department of Justice (DoJ) has cleared the pending $54 billion acquisition of pharmacy benefit manager Express Scripts by Healthcare insurer Cigna Corp. 18 September 2018
Pharmaceutical
Allergan on Friday announced it is expanding its already successful Botox medical aesthetics business with the acquisition of Bonti, a privately held clinical-stage biotechnology company. 17 September 2018
Pharmaceutical
As US Food and Drug Administration rejects approval of GlaxoSmithKline’s Nucala for COPD, the company has been touting new data for the drug in asthma. Also on the US regulatory front, the FDA Breakthrough designation of AstraZeneca’s tezepelumab is seen as important for the drugmaker’s asthma ambitions, while in Europe, Merck & Co gained approval of Keytruda in the first-line cancer setting. Elsewhere, Gilead Sciences and Galapagos released positive results with filgotinib, a rheumatoid arthritis drug recently rejected by AbbVie, and Boehringer Ingelheim took up the option to acquire ViraTherapeutics. 16 September 2018
Pharmaceutical
Supernus Pharmaceuticals has entered into a merger agreement to acquire Biscayne Neurotherapeutics, a privately-held company developing a novel treatment for epilepsy. 14 September 2018
Pharmaceutical
Japan's Takeda Pharmaceutical is considering selling the ophthalmics division of Shire (LSE: SHP) directly after buying the rare disease specialist, according to a report from Bloomberg. 14 September 2018
Pharmaceutical
Sanofi today announced that it will change the organizational structure of two of its Global Business Units (GBU) to provide greater focus on its operations in mature markets and across emerging markets. 13 September 2018
Biotechnology
Based on its strong focus on the Asian market, French metabolic diseases biotech company Poxel has made another significant move to solidify its position, forming a fully-owned Japanese subsidiary, Poxel KK. 13 September 2018
Biotechnology
German family-owned pharma major Boehringer Ingelheim has exercised its option to acquire all the share of EMBL Ventures’ portfolio company ViraTherapeutics, based in Innsbruck, Austria. 13 September 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze